August 07, 2020
3 min watch
Save
VIDEO: Synthetic peptide may yield durable vision gains in retinal diseases
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video from the virtual American Society of Retina Specialists meeting, Peter K. Kaiser, MD, discusses AXT107, a synthetic peptide designed to treat wet age-related macular degeneration and macular edema.
Soon to enter clinical trials, AXT107 (AsclepiX Therapeutics) develops a gel-like depot when injected, which may lead to extended durability.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.